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The Red Devil Revisited*
Juan Carlos Plana, MDCleveland, OhioDoxorubicin, or “the red devil,” as patients affec-
tionately call it because of its color as it ﬂows through
their intravenous catheters, is without a doubt one of
the most widely prescribed and effective cytotoxic
drugs, used in the treatment of cancer. However, its
use has been limited by its cardiac toxicity.
See page 877
When I went to medical school, I was taught
that conceptually, the toxicity of doxorubicin and
anthracyclines in general could be compared with
that of acetaminophen, such that as long as I oper-
ated within “the safe dose,” patients with cancer
would derive only beneﬁts, not toxicity. I do not
believe that my teachers are to be blamed for this
thinking. If we take a look at the original von Hoff
curve, published in 1979, although there is a con-
tinuum of increasing probability of congestive heart
failure, the slope of the curve remained relatively ﬂat
until the cumulative dose exceeded 550 mg/m2. Von
Hoff et al. (1) reported an overall incidence of heart
failure of 2.2%. With the concern that this incidence
was not an accurate reﬂection of the real severity
of this adverse event, further work was done by
Swain et al. (2). They indeed found a higher overall
incidence of heart failure of 5.1%. The estimated
cumulative percent of patients was 5% at a cumulative
dose of 400 mg/m2, rising more dramatically to 26%
at a dose of 550mg/m2. In the curve redrawn by those
investigators, the slope of the curve appeared to
change at 450 mg/m2, with the majority of events
occurring at cumulative doses exceeding 500 mg/m2.*Editorials published in JACC: Cardiovascular Imaging reﬂect the views of
the authors and do not necessarily represent the views of JACC: Cardio-
vascular Imaging or the American College of Cardiology.
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were almost superimposable and, again, essentially
ﬂat at low cumulative doses in the range of 100 to
300 mg/m2, at which heart failure was unusual. As a
result , oncologists have felt “relatively safe” during the
past 10 years administering anthracycline-based reg-
imens at these low doses.
In this issue of iJACC, Drafts et al. (3) report
their work using noninvasive imaging to detect evi-
dence of subclinical cardiovascular disease in patients
treated with low to moderate doses of anthracycline-
based chemotherapeutic agents (50 to 375 mg/m2).
They ﬁll a knowledge gap, as very little is known
in terms of what actually happens in the hearts of
patients treated with these low doses.
Using cardiac magnetic resonance, the gold
standard for left ventricular (LV) volumes, and left
ventricular ejection fraction (LVEF) measurement,
Drafts et al. (3) found that LV end-diastolic volume
remained unchanged throughout therapy. LVEF
decreased, and as a result, end-systolic volume
increased. The decline in LVEF was paralleled by
worsening of midwall circumferential strain.
Although decision making in cardio-oncology is
very sensitive, and always based on the risk/beneﬁt
ratio, it is important to note that anthracyclines were
actually started in 6 patients (11%) with mild LV
dysfunction (LVEF <50% at baseline). Excluding
these patients, an unexpectedly large percent of
participants (26%) had developed mild LV
dysfunction (LVEF <50%) at 6-month follow-up
after the end of therapy. The same percent of pa-
tients in this cohort exhibited evidence of subclinical
myocardial injury, as demonstrated by elevations of
troponins, before the administration of the last dose
of anthracyclines. Brain natriuretic peptide levels did
not increase. The investigators’ ﬁndings are consis-
tent with the biomechanical model proposed by
Mann and Bristow (4). In this case, the index event is
the administration of anthracyclines. Recent work by
Zhang et al. (5) indicates that doxorubicin induces
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887deoxyribonucleic acid (DNA) double-strand breaks
and transcriptome changes through the formation of
ternary complexes (Top2-doxorubicin-DNA cleavage
complex). The end result is apoptosis of the cardiac
myocytes (veriﬁed by the elevations in troponins). As
cardiac mass is lost, systolic function suffers early
(prevalent reductions in LVEF and circumferential
strain at 6 months). Despite the reduction in systolic
performance, ﬁlling pressures remained normal
(normal brain natriuretic peptide levels).
To further understand the injury, Drafts et al. (3)
also performed late gadolinium enhancement im-
aging. Excluding the patients with prior myocardial
infarctions and revascularization who exhibited
ﬁndings consistent with myocardial scar, all other
baseline and 6-month studies were unremarkable.
These ﬁndings contradict the pathologic examina-
tions, in which apoptosis is accompanied by
myocardial ﬁbrosis (MF) in patients treated with
anthracyclines (6). It is unclear if this is a conse-
quence of the short follow-up available in this study
or a limitation of the technique used to detect
the MF. Late gadolinium enhancement requires
normal reference myocardium. Anthracycline-induced
cardiomyopathy may induce diffuse myocardial
involvement, leaving no normal background myo-
cardium to be used for reference. A new cardiac
magnetic resonance–based technique has been used
in which the measurement of myocardial T1 pro-
vides a quantitative measure of the extracellular
volume, most likely reﬂecting the pathologic extent
of MF (7). In a recent study by Neilan et al. (8),
extracellular volume was elevated in anthracycline-
treated patients compared with age-matched and
sex-matched controls, suggesting the presence of
MF. Although MF is the most likely cause of the
extracellular matrix expansion, other conditions such
as edema and inﬁltration could not be excluded. It is
also important to realize that the patients evaluated
by Neilan et al. (8) presented much later after
receiving their anthracycline-based regimens (a me-
dian of 84 months).
From the mechanistic standpoint, the inves-
tigators also open our eyes with a new ﬁnding.
Participants exhibited increases in thoracic aortic
pulse-wave velocity, a measure of aortic stiffening.
Previous work by Crone et al. (9) illustrated in an
animal model the effect of afterload increase in a
model of trastuzumab-based cardiotoxicity using a
knockout model. This ﬁnding reminds us of the
importance of ventriculoarterial coupling and em-
phasizes the importance of understanding the heart
as part of an integrated cardiovascular system and
not in isolation.The most important question to ask is how we ﬁt
this piece of data into the big picture.
New “real-world” and Medicare data conﬁrm
the rate of heart failure in patients receiving
anthracyclines at about 5%, as previously described
by Swain et al. (10,11). It is unclear to me who
among the 26% of patients with reduced LVEFs at
the 6-month follow-up reported in this study will
improve, who will stay the same, and who will
progress to be part of the 5% of patients who actually
develop heart failure syndrome. I believe that further
work needs to be done to understand the potential
role of myocardial inﬂammation and ﬁbrosis in the
risk stratiﬁcation of these patients and the optimal
method to identify it.
The investigators also measured the effect of
anthracyclines on the quality of life, ﬁnding a nega-
tive impact over time. Although interesting, I am
not sure what is to be blamed for the perceived
deterioration in the quality of life: the cancer, the
chemotherapy, or its well-recognized proﬁle of side
effects. It would be intuitive to expect a worse
perception of quality of life in patients who develop
cardiotoxicity. Although the investigators observed a
trend in this direction, it did not prove to be of
statistical signiﬁcance.
I propose looking at the ﬁndings of this study not
as a glass half empty but as a glass half full. Being
aware that anthracyclines at low doses are not
“innocent” and are actually associated with a rate of
early LV dysfunction much higher than anticipated
gives us the option of reacting with a strategy of
aggressive surveillance and treatment of cardiotox-
icity. On the bright side, recent work by Cardinale
et al. (12) has challenged the concept of the “irre-
versibility of anthracycline-induced cardiomyopa-
thy.” Their data demonstrate that the condition is
potentially reversible, as long as it is recognized
early. We can then integrate the ﬁndings of the
present study, hypothesizing that the development
of heart failure may be potentially prevented in these
patients if heart failure therapy is started at a point
at which, just as in this group of patients, end-
diastolic volume is still normal and LV remodeling
has not occurred. As a result, it becomes of para-
mount importance to follow the LV dimensions and
systolic function of these patients during and
immediately after therapy and to do so using sen-
sitive techniques, including strain imaging, which
would allow very early detection and aggressive
treatment of cardiotoxicity, hopefully at a point at
which the LVEF has not changed.
Finally, recognizing that cardiac disease indeed
represents the most common reason for mortality
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888among cancer survivors, we are working on chang-
ing our model of care for these patients through the
creation of cardio-oncology centers of excellence
across the nation. Oncologists, prevention special-
ists, radiologists, and heart failure cardiologists are
now making decisions together before, during, and
after chemotherapy in a patient-centered model,
with the goal of optimizing cancer therapy while
minimizing cardiac toxicity.
I am conﬁdent that this model, along with
elegant contributions to our knowledge such as thatof Drafts et al. (3), will give us, through better
understanding of the mechanisms of disease, the
option of developing treatment strategies that
will secure cancer treatment with minimal or no
toxicity.
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